Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (NEOS)

Novartis logo

Novartis

Status and phase

Enrolling
Phase 3

Conditions

Multiple Sclerosis (MS)

Treatments

Drug: Siponimod
Drug: Ofatumumab
Other: Fingolimod placebo
Drug: Fingolimod
Other: Siponimod placebo
Other: Ofatumumab placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04926818
CBAF312D2301

Details and patient eligibility

About

Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis

Full description

The study is divided into a Core Part and Extension Part. The Core Part is a 24-month, double-blind, triple dummy, randomized, 3-arm active-controlled in children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). The Extension Part is 60-month (5 year) open label (except for first 12 weeks transition which will remain double-blind) treatment for patients who complete the Core Part of the study and meet all inclusion/exclusion criteria. The targeted enrollment is 180 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ≤40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years.

Enrollment

180 estimated patients

Sex

All

Ages

10 to 17 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Between 10 to <18 years of age (i.e., have not yet had their 18th birthday) at randomization
  • Diagnosis of multiple sclerosis
  • EDSS score of 0 to 5.5, inclusive
  • At least one MS relapse/attack during the previous year or two MS relapses in the previous two years prior or evidence of one or more new T2 lesions within 12 months

Exclusion criteria

  • Participants with progressive MS
  • Participants with an active, chronic disease of the immune system other than MS
  • Participants meeting the definition of ADEM
  • Participants with severe cardiac disease or significant findings on the screening ECG.
  • Participants with severe renal insufficiency

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

180 participants in 3 patient groups

ofatumumab - 20 mg injection/ placebo
Experimental group
Description:
Ofatumumab as a solution for injection in an autoinjector containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content) for subcutaneous administration. A loading dose at Day1, Day 7 and Day 14 and then injections every 4 weeks/ 6 weeks (depending on patient's body weight).
Treatment:
Other: Ofatumumab placebo
Drug: Ofatumumab
siponimod - 0.5 mg, 1 mg or 2 mg/ placebo
Experimental group
Description:
Siponimod tablet administered orally once daily. Titration period, Day 1 to Day 6, first dose is either 0.1 mg or 0.25 mg up to daily dose of either 0.5 mg, 1 mg or 2 mg (depending on CYP2C9 genotype and body weight).
Treatment:
Other: Siponimod placebo
Drug: Siponimod
fingolimod - 0.5 mg or 0.25 mg/ placebo
Active Comparator group
Description:
Fingolimod capsule administered orally once daily at a dose of either 0.5 mg or 0.25 mg (depending on patient's body weight).
Treatment:
Drug: Fingolimod
Other: Fingolimod placebo

Trial contacts and locations

74

Loading...

Central trial contact

Novartis Pharmaceuticals; Novartis Pharmaceuticals

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems